Dr Reddy’s to distribute Takeda’s QDENGA dengue vaccine in India from H1 2027
Dr Reddy’s Laboratories will exclusively promote and distribute Takeda’s QDENGA in India’s private market following CDSCO marketing authorisation. The two-dose dengue vaccine, for people aged 4–60, is expected to be available in the first half of 2027.
What happened
Dr. Reddy’s Laboratories · Dr Reddy’s will exclusively promote and distribute Takeda’s QDENGA dengue vaccine in India’s private market, targeting a first-half
Key facts
- First half of 2027 expected India private-market availability
- CDSCO marketing authorisation in July 2026
- Eligible age group: 4-60 years
- Reported dengue cases increased 11-fold over two decades
- All four dengue serotypes (DENV-1 to DENV-4) circulating
Why this matters
Dr Reddy’s gains an exclusive, high-value private-market vaccine mandate that can leverage its physician, vaccinator and nationwide distribution network ahead of QDENGA’s expected H1 2027 launch.
What to watch
- Final launch timing, pricing and pack economics in H1 2027
- Private-market reimbursement, corporate health-benefit inclusion or insurer coverage
- Clinical-society guidance and physician sentiment on broad dengue vaccination use
- Evidence on completion rates for the second dose and effectiveness in Indian real-world settings
- Severity and geographic spread of dengue seasons in 2026–2028